Associated equity: Context Therapeutics
Context Therapeutics is a clinical-stage biopharma company developing therapeutics for solid tumors. Following a strategic pivot, the core pipeline focus will be on CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6 positive tumors, which is in preclinical development with plans for an IND application filing in Q124.
Context Therapeutics — 3 videos in collection
Context Therapeutics (Nasdaq: CNTX) is a clinical-stage biopharmaceutical company committed to advancing medicines for female cancers. The company’s pipeline includes small molecule and bi-specific antibody drug candidates that target cancer signaling pathways. ONA-XR (onapristone extended release), a novel, first-in-class potent and selective progesterone receptor antagonist, is currently in three Phase II clinical trials and one Phase Ib/II clinical trial in hormone-driven breast, ovarian and endometrial cancers. Context is also developing CTIM-76, a selective CLDN6xCD3 bi-specific antibody for CLDN6 positive tumors, currently in pre-clinical development.
In this webinar, the Context Therapeutics management team, along with two experts in the field, discuss the company’s CLDN6 program and the recently announced selection of CTIM-76, a T cell-engaging bi-specific antibody, as its lead clinical development candidate.
Get access to the very latest content matched to your personal investment style.